MMM250103C124000
- 6.22
- -0.11-1.74%
3M Newsroom
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
9 Analysts Have This To Say About 3M
3M Is Maintained at Underperform by RBC Capital
3M Analyst Ratings
Santa Claus Came Without Rallying the Troops | Live Stock
RBC Capital Maintains 3M(MMM.US) With Sell Rating, Cuts Target Price to $96
U.S. Companies With Potential Pension Risk Transfer Restructuring Opportunities
Jefferies Maintains 3M(MMM.US) With Hold Rating, Maintains Target Price $146
Dow Up 229 Points On Gains For 3M, Chevron Shares
Unusual Options Activity: SQ, MSTR and Others Attract Market Bets, SQ V/OI Ratio Reaches 113.7
Market Falling Monday, With Few Santa Clause 'Rally' Days Left | Live Stock
Weekly Buzz: So far, Santa is Letting us Down
Friday Market Pulls Back, Led by Mag Seven Decline | Live Stock
10 Industrials Stocks With Whale Alerts In Today's Session
JPMorgan Says These 2 Value Stocks Are Among Its 'Best Idea' Picks for 2025
Everbright: Maintains the "Buy" rating for ASCLETIS-B. ASC47 combined with semaglutide shows superior effects.
Everbright released a research report stating that ASCLETIS-B (01672) is actively laying out its strategies in the MASH and weight loss sectors, and its progress is among the best in the country. Considering the company's effective control over various expenses, the net income forecast for 2024-2025 has been adjusted to -0.261/-0.313 billion yuan (previously -0.284/-0.34 billion yuan), and a new net income forecast for 2026 is -0.322 billion yuan, maintaining a "Buy" rating. The company released experimental data on the weight loss and muscle gain treatment drug ASC47 combined with semaglutide in obese mice; this drug is a fat-targeting, once-a-month subcutaneous injection of a thyroid hormone receptor β agonist.
Why the 'Dogs of the Dow' Stocks Just Might Deliver in 2025
3M Company (MMM): Among the Biggest Dividend Cuts and Suspensions of 2024
TCL has released the small blue wing C7 fresh air Air Conditioner, aiming to improve the "sleep" for 0.3 billion people suffering from insomnia.
According to a report from Sina Technology on the evening of December 23, TCL recently announced the launch of the TCL Xiaolan Wing C7 fresh air Air Conditioner, focusing on user needs in sleeping scenarios for bedrooms and purification scenarios for living rooms, aiming to create the most suitable air solution that meets smart health standards for consumers. Research data shows that the number of people suffering from insomnia in China is increasing year by year, surpassing 0.3 billion by 2023. Among the four major factors affecting sleep are temperature, noise, air quality, and human airflow sensation. It is introduced that the TCL Xiaolan Wing C7 fresh air Air Conditioner is designed to improve sleep, committed to utilizing AI sleep fresh air technology to create a healthy atmosphere.